ELITE PHARMACEUTICALS INC /NV/ Cash Flow Statement
ELTP|14 years of annual SEC 10-K data (FY2011-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 14 fiscal years. All figures from audited SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -0.19 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | - | -$4.3M | $20.1M | $3.6M | $8.9M | $5.1M | -$2.2M | -$9.3M | -$3.7M | $3.8M | -$683.0K | $5.2M | $1.5M | -$15.1M |
| Depreciation & Amortization | - | $1.2M | $1.3M | $1.3M | $1.2M | $1.3M | $1.3M | $1.3M | $996.4K | $714.5K | $666.5K | $581.9K | $423.3K | $484.2K |
| Operating Cash Flow | - | $7.5M | -$3.2M | $3.3M | $6.5M | $3.2M | -$1.8M | -$6.8M | -$4.8M | -$7.9M | -$2.8M | -$15.1M | -$1.9M | -$394.1K |
| Capital Expenditures | - | $1.6M | $809.7K | $5.7M | $498.6K | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | $5.8M | -$4.0M | -$2.4M | $6.0M | - | - | - | - | - | - | - | - | - |
| FCF Margin | - | 6.9% | -7.1% | -7.0% | 18.6% | - | - | - | - | - | - | - | - | - |